- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05230537
Een gemaskeerd, placebo-gecontroleerd onderzoek om iptacopan te beoordelen bij leeftijdsgebonden maculaire degeneratie
Een gerandomiseerde, door deelnemers en onderzoekers gemaskeerde, placebogecontroleerde, multicenter, proof-of-concept-studie om de veiligheid en werkzaamheid van LNP023 (Iptacopan) te beoordelen bij patiënten met vroege en intermediaire leeftijdsgebonden maculadegeneratie
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).
Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:
- Iptacopan (LNP023) oral capsules
- Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Shanghai, China, 200080
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150001
- Novartis Investigative Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300020
- Novartis Investigative Site
-
-
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research and Development Center LLC
-
-
-
-
-
London, Verenigd Koninkrijk, SE5 9RS
- Novartis Investigative Site
-
Southampton, Verenigd Koninkrijk, SO16 6YD
- Novartis Investigative Site
-
-
-
-
California
-
Fullerton, California, Verenigde Staten, 92835
- Retina Consultants of Orange County
-
Huntington Beach, California, Verenigde Staten, 92647
- Salehi Retina Institute
-
Rancho Cordova, California, Verenigde Staten, 95670
- Martel Eye Medical Group
-
Sacramento, California, Verenigde Staten, 95841
- Retinal Consultants Medical Group Inc
-
Santa Barbara, California, Verenigde Staten, 93103
- California Retina Consultants
-
-
Colorado
-
Durango, Colorado, Verenigde Staten, 81303
- Southwest Retina Research Center
-
-
Florida
-
Deerfield Beach, Florida, Verenigde Staten, 33064
- Advanced Research LLC
-
Delray Beach, Florida, Verenigde Staten, 33484
- Retina Center Of South Florida
-
St. Petersburg, Florida, Verenigde Staten, 33711
- Retina Vitreous Associates of Florida
-
-
Indiana
-
Carmel, Indiana, Verenigde Staten, 46032
- Midwest Eye Institute
-
-
Louisiana
-
Metairie, Louisiana, Verenigde Staten, 70001
- Retina Associates New Orleans
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21209
- Retina Care Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Opthamalic Consultants of Boston
-
-
New Jersey
-
Bloomfield, New Jersey, Verenigde Staten, 07003
- Envision Ocular LLC
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27705
- Duke Eye Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
- Retina Northwest PC
-
-
Tennessee
-
Germantown, Tennessee, Verenigde Staten, 38138
- Charles Retina Institute
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78793
- Austin Research Center for Retina
-
Bellaire, Texas, Verenigde Staten, 77401
- Retina Consultants TX Rsrch Ctr
-
Dallas, Texas, Verenigde Staten, 75231
- Retina Foundation
-
Fort Worth, Texas, Verenigde Staten, 76104
- Texas Retina Associates
-
Houston, Texas, Verenigde Staten, 77030
- Retina Consultants of Houston PA
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female participants ≥ 50 years of age
- Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
- Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
- Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
- Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
- If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.
Exclusion Criteria:
- History or current diagnosis of ECG abnormalities indicating significant safety risk, such as clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
- History of familial long QT syndrome or known family history of Torsades de Pointes
- History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
- History of end stage kidney disease requiring dialysis or renal transplant
- History of malignancy of any organ system
- History of solid organ or bone marrow transplantation
- History of recurrent meningitis or history of meningococcal infections despite vaccination
- History of immunodeficiency diseases, including a positive Human Immunodeficiency Virus test result at Screening
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
- Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
- Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Iptacopan (LNP023)
Iptacopan (LNP023) oral use capsules |
oral capsules |
|
Placebo-vergelijker: Placebo
Placebo matched to study drug, oral use capsules |
oral capsules |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging
Tijdsspanne: Baseline/Day 1 through Month 24
|
OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines |
Baseline/Day 1 through Month 24
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The incidence of ocular and non-ocular adverse events (AEs)
Tijdsspanne: Baseline/Day 1 through Month 24
|
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. |
Baseline/Day 1 through Month 24
|
|
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye
Tijdsspanne: Baseline/Day 1 through Month 24
|
Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye
Tijdsspanne: Baseline/Day 1 through Month 24
|
ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye
Tijdsspanne: Baseline/Day 1 through Month 24
|
Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read. |
Baseline/Day 1 through Month 24
|
|
Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye
Tijdsspanne: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
|
Pharmacokinetics - concentrations of LNP023 related to trough samples
Tijdsspanne: Baseline/Day 1 through Month 24
|
Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method. |
Baseline/Day 1 through Month 24
|
|
Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye
Tijdsspanne: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Ziekten van het zenuwstelsel
- Oogziekten
- Sensatiestoornissen
- Ziekten van het netvlies
- Retinale degeneratie
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Maculaire degeneratie
- Geografische atrofie
- Natte maculaire degeneratie
- Gezichtsstoornissen
- Iptacopan
Andere studie-ID-nummers
- CLNP023E12201
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .